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A vexing problem after hematopoietic cell transplantation (HCT)for leukemia is assessing the biologic significance of low numbers of cells "suspicious" for relapse seen in morphologic review of peripheral blood smears (PBSs
Despite substantial advances in the treatment of hematologic malignant neoplasms by bone marrow transplantation or hematopoietic stem cell transplantation, relapse remains a major cause of failure. The laboratory tests for diagnosing early relapse or minimal residual disease include conventional and molecular cytogenetics, identification of mixed chimerism using variable nontandem repeats (VNTR) or fluorescence in situ hybridization (FISH), polymerase chain reaction amplification of tumor-specific translocations or gene rearrangements, multidimensional flow cytometry (MDF), and morphologic identification. 17 While such studies can be used for screening or confirming a diagnosis, the hierarchy of use reflects the sensitivity and specificity of a positive test, the turnaround time, costs, and the ability to provide informative data in the context of the particular leukemia or donor-host setting.
Complete blood count (CBC) with smear review or manual differential is an inexpensive and rapid screening test for relapse. The usefulness of the CBC stems from the fact that it is a frequently performed test that often provides the first inkling of relapse evidenced by decreasing blood cell counts or the finding of cells suggestive of relapse on a morphologic review of a peripheral blood smear (PBS).
In the current milieu, maintaining quality service is in conflict with increasing financial pressures to replace the more labor-intensive, expensive, and imprecise manual differential blood cell count with the more rapid and inexpensive automated differential cell count. 8 Despite improved sensitivity of blast detection by the newest hematology analyzers, [9] [10] [11] in the hematopoietic cell transplant (HCT) differential, the efficiency of the software-generated WBC operator alert flags in different hematology analyzers ranges from 72% to 96%. 9 "" The false-negative results increase greatly when the total WBC count falls to less than 1,000/uL (1 x 10 9 /L), especially when the blast count is low and consists of low volume lymphoid-monocytoid cells. 12 The use of an automated differential to screen for early relapse in the transplant milieu is further diminished by the frequent to almost universal presence of software-generated operator alerts, the frequent (60%-67%) inaccuracy of the interpretive messages, and the need to morphologically review these flagged differential counts. 13 This quandary is compounded by quantitative changes in blood, such as the premature release of myeloblasts that follows the use of hematopoietic growth factors or after myeloablative damage to marrow microenvironment. 14 This necessitates manual differential or smear verification to confirm or improve specificity of most automated differential counts obtained after HCT to treat malignant hematopoietic neoplasms. Preparing buffy coat smears, advocated as a way to improve the precision and accuracy of morphologic evaluation, 15 leads to increased time and costs without answering the primary question: is the small population of blastic or immature cells malignant?
In the present study, 27 transplant recipients in apparent remission had low numbers of cells suggestive of relapse detected in their peripheral blood differential smears. We studied the relationship of these cells classified as normal or malignant based on the aberrant antigen expression detected by MDF 16 and other potential variables to the subsequent development of relapse.
Materials and Methods
Patient Selection
At the Fred Hutchinson Cancer Research Center, Seattle, WA, CBCs are done daily for inpatients, 2 to 3 times a week for outpatients, or more frequently if patients are receiving transfusional support. All posttransplant CBCs include a manual WBC differential. Atypical cells or those suggestive of relapse in posttransplant CBCs are circled and reviewed by a pathologist. In May 1995, we began to study the CBCs with cells suggestive of relapse by doing MDF. All 27 patients met the following criteria: (1) posttransplant to treat hematologic malignant neoplasm; (2) in apparent hematologic remission by available information from morphologic examination, previous MDF studies, and cytogenetic data; (3) contained low numbers of cells that were abnormal, immature, or blastic, suggestive of relapse, on CBC manual differential count when confirmed by pathologist review between May 1, 1995, and December 31, 1997; and, (4) MDF was performed on a blood specimen, bone marrow aspirate (BMA), or both between 0 and 9 days (median, 2 days) after the abnormal cells were seen in the PBS.
Laboratory Studies
The decision to obtain an MDF sample from blood or a nonscheduled BMA (usually scheduled on days 28, 56, and 80 after the transplantation) rested with the patients' attending clinicians. When the BMA was performed, 3 separate samples were obtained. The first was prepared for morphologic evaluation by a pathologist. The blood, BMA smears, and touch preparations were Wright-Giemsa stained. The particle sections, and in some cases, additional marrow biopsy specimens, were stained with H&E and periodic acid-Schiff, as well as reticulin stain of the biopsy specimens.
Multidimensional Flow Cytometry
The second marrow aspiration syringe containing heparin was sent for MDF. Most of the peripheral blood samples drawn for MDF also contained heparin rather than EDTA because of the longer stability of the cells with heparin. The technique of MDF simultaneously assesses several quantitative cellular characteristics using antibody panels, CD45 gating plus forward and side scatter (SSC), creating a 5-dimensional space, hence a multidimensional analysis. 1719 In short, a working dilution of the titered monoclonal cocktails ITable II, CD45 peridinin-chlorophyll a (CD45 PerCP), and 0.1 mL of well-mixed heparinized BMA or peripheral blood were incubated for 20 minutes at room temperature in the dark. The erythrocytes were lysed by adding 3 mL NH 4 C1 (0.83%, buffered with KHC0 3 , pH 7.2) for 5 minutes at 37°C. The cells were then pelleted; washed once in a solution of phosphate-buffered saline, 2% fetal calf serum, and 0.1 % sodium azide solution; pelleted again; and resuspended in phosphate-buffered saline with 1% paraformaldehyde. Acquisition of data was performed on the CytoronAbsolute (Ortho Diagnostics, Raritan, NJ) using ImmunoCount software (Ortho Diagnostics). Data analysis was performed with Winlist software (Verity House, Topsham, ME). In a standard 3-color immunofluorescence protocol, forward light scatter and SSC were collected along with 3-color antibody combinations to generate 5 characteristics per cellular event. 17 Peripheral blood specimens or BMAs from the identified patients were quantified by MDF analysis. The blast cells based on this gating procedure were patterned relative to the antigen expression observed in normal bone marrow using a standardized panel of 3-color reagents.
617 " 23 Patients with a diagnosis of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous
• leukemia (CML) underwent assays using a myeloid panel, while the patients with acute lymphoblastic leukemia (ALL) were assessed with a B-lymphoid panel. Abnormal timing in the appearance of normally expressed antigens along with the deviant expression of nonlineage antigens are the characteristics of neoplastic cells. A specimen was defined as having aberrant blasts when 2 analysts agreed that the population was at least 0.5 decades disparate from the relative intensity of antigens expressed on corresponding normal cells. Usually, multiple differences from normal could be detected. The types of aberrancies assessed were as follows:
(1) lineage infidelity; (2) asynchronous expression; (3) intensity abnormalities; and (4) antigen absence. Aberrant immunophenotypic populations as infrequent as 0.3% could be identified by using this approach. 617 The flow cytometric report was generated without the knowledge of results of other tests.
Analysis of Sorted Blasts
In some cases, MDF analysis found neoplastic cells in patients with no clinical indication of relapse, a previously undetected de novo clone, or a proportional increase in phenotypically normal myeloblasts or lymphoblasts. The suspect blastic population was concentrated by cell sorting. In cases of a host-donor sex difference, they were studied by using FISH with X-and Y-chromosome-specific DNA probes and/or tumor specific translocation probe when available. The sorted cells were streaked on a slide and digested in pepsin solution (0.1 mg/mL in a 0.01-mol/L concentration of hydrochloric acid) at 37°C for 3 minutes and fixed in 4% buffered formalin for 15 minutes. They were treated in 2x SSC at 72°C for 10 minutes and denatured in 70% formamide/2x SSC at 72°C for 3 minutes, followed by 70%, 95%, and 100% ethanol at -20°C and air drying.
The X probe is locus DXZ1 (plasmid pBSXBAM5.5), and the Y probe is locus DYZI (plasmid pGEMY3.4). They are labeled with digoxigenin and biotin, respectively, by nick translation. The X and Y probes, each at 1 mg/mL, in hybridization buffer (50% formamide, 2x SSC, 10% dextran sulfate, 1 mg/mL salmon sperm DNA) were mixed and denatured at 72°C, cooled on ice, and applied to the slide under a coverglass, and the edges were sealed with rubber cement. The slides were incubated overnight in a humidified chamber at 42°C. The slides were washed in 55% formamide-2x SSC at 45°C for 15 minutes. They were simultaneously detected with anti-digoxigenin-fluorescein (catalog no. 1207 741, 1:500 dilution, Boehringer-Ingelheim, Ridgefield, CT) and Texas red-avidin (catalog no. A-2006, 1:500 dilution, Vector Laboratories, Burlingame, CA) in 4x SSC for 30 minutes in the dark at room temperature. Slides were then rinsed with 4x SSC and lx PBS for 5 minutes each. Slides were counterstained with 4 ' , 6-diamidino-2-phenylindole (0.25 mg/mL) and mounted in Vectashield (catalog no. H-7000, Vector Laboratories). Slides were examined using a Zeiss Axioscope (Zeiss, Thornwood, NY) equipped with epifluorescence with a triple band pass filter. If needed, VNTR was performed to indicate the fraction of host cells. The results from the sorted population were compared with sorted benign cells within the same specimen. 
Cytogenetics
A third BMA syringe containing heparin was analyzed by conventional cytogenetics for karyotype and/or by FISH. Twenty metaphases routinely were analyzed for patients with same-sex donors who had an acquired clonal chromosomal abnormality, including a Philadelphia chromosome, identified before the transplantation or a constitutional abnormality not present in the donor. 1 Samples from patients with an opposite-sex donor, excluding those with a diagnosis of CML, were analyzed by molecular scoring of 500 interface nuclei after FISH with a dual-color X and Y probe mixture. 3 The cells were fixed in methanol-acetic acid and examined by combined XY FISH without pretreatment, as described previously. When indicated, samples from patients with a same sex-donor were studied for chimerism by VNTR.
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Statistical Analysis
Morphologic relapse, defined as more than 5% blasts in the BMA within 42 days of the abnormal manual CBC count-driven MDF, was taken as the outcome variable for analysis. Justification for this definition was taken from our previous study, 20 coupled with our experience that identification of variables associated with relapse in the immediate future is clinically meaningful. The association of various explanatory variables with the probability of morphologic relapse defined in this manner was examined by using exact logistic regression. The explanatory variable of primary interest was the MDF characterization of the abnormal or blastic cell population, where this characterization was categorized as benign (normal) or malignant (aberrant blasts). Three additional explanatory variables were studied: (1) change in the absolute neutrophil count (ANC) during the week preceding the MDF, categorized as decreasing (decrease of >50%), increasing (increase of >50%), or stable (increase or decrease <50%); (2) frequency of cells suggestive of relapse, categorized as sporadic (occurring once) or multiple (seen on more than 1 day whether consecutive or intermittent); and (3) status at transplantation, categorized as remission (<5% blasts) or relapse (>5% marrow blasts).
Two patients with relapsed MDS and 1 with CML in accelerated phase or blast crisis were considered in relapse at the time of transplantation. One patient had 2 abnormal CBC-driven MDF tests, and, for purposes of analysis only, the result of the first test (which was benign) was used. No adjustments were made for multiple comparisons, and P values associated with regression models were obtained using exact methods. Odds ratios were estimated by exponentiating the parameter estimates resulting from appropriate regression models. The probability of relapse-free survival was estimated by using the method of Kaplan and Meier, in which patients alive without relapse at last contact are censored at this time.
Results
The relevant features of the 27 patients who met the criteria for inclusion in the study cohort are given in ITable 21. The age of 13 females and 14 males ranged from 3 to 57 years (median, 37 years). Two of 27 patients were receiving granulocyte colony-stimulating factor at the time they were studied. All patients received allogeneic transplants from 11 matched-related, 12 matched-unrelated, and 4 mismatched related donors. The diseases preceding transplantation were as follows: AML, 17; MDS, 2; ALL,6; and CML, 2. The percentage of peripheral blood cells that by morphologic examination suggested relapse ranged from rare to 20% (median, < 1%); the maximum absolute count of cells suggestive of relapse was 760/uL (0.76 x 10 9 /L). The original diagnostic samples were obtained at other institutions; therefore, a multidimensional immunophenotypic characterization of the initial tumor was not available. At the time of referral for bone marrow transplantation, 20 of 27 patients had detectable tumor. For patients identified as having cells suggestive of relapse, a blood specimen, BMA, or both were submitted for flow cytometric analysis within 9 days (range, 0-9 days; median, 2 days) of finding the cells in the PBS that suggested relapse. These flow cytometric specimens were analyzed with panels of reagents specific for detection of lymphoid or myeloid abnormalities (Table 1) . Individually created antibody panels were not implemented. The immature cells were characterized as normal or aberrant depending on the intensity of antigen expression for all antibodies tested in comparison with normal bone marrow blasts. 6 - 21 As detailed in the next section, MDF analysis on specimens from 17 of 27 patients contained cells with normal phenotypes, while 10 of 27 were classified as abnormal. IFigure II shows the probability of relapse-free survival after MDF for each of these groups.
MDF With Normal (Benign) Immunophenotype
The MDF specimens from 17 patients were identified as having normal blasts ranging from less than 0.2% to 14%. Seven of the 17 patients were transplanted in remission. Ten of 17 had a rising ANC, while the remaining patients had stable or decreasing ANC. In 7 of 17, peripheral blood cells suggestive of relapse were observed on more than 1 day. By flow cytometric • Unique patient number (UPN) 10747 contained increased normal blasts. This patient, who underwent hematopoietic stem cell transplantation (HSCT) for ALL soon after induction into remission, exhibited up to 20% blasts in her peripheral blood on multiple days after transplant from her father (Figure 1 ). Before transplantation, no characterization of the leukemia could be made since she arrived for treatment in remission. The day 20 peripheral blasts were characterized by MDF as myeloblasts rather than lymphoblasts, with expression of CD33, CD 13, CD34, without expression of CD 19 or other lymphoid marker IFigure 21. This blast population of cells was sorted based on expression of CD34 and was shown to be 99.5% male (donor-positive) by FISH analysis. When relapse occurred on day 182, the blasts had an aberrant lymphoid phenotype.
Cytogenetics was performed on a BMA obtained within 1 week of the detection of peripheral blood cells that suggested relapse in 15 of 17 of patients classified by MDF as having benign blasts. All 15 patients were shown to have a normal karyotype at this time. In 6 of the 17 patients defined as normal by MDF analysis, relapse eventually occurred. One of these 6 patients, UPN 10026, relapsed 21 days after the MDF. In the previous marrow specimen obtained 23 days earlier, neither flow cytometry nor cytogenetics detected abnormal cells. At relapse, the phenotype of the abnormal cells was identical to that observed before transplantation. Retrospective analysis of the earlier flow cytometric data showed less than 0.1% cells with this aberrant phenotype, below our limit of detection. The other 5 patients relapsed at 54, 76, 162, 203, and 337 days after benign flow cytometric analysis. Of the 6 patients, the 3 who were later studied with MDF all acquired a blastic population immunophenotypically aberrant from the normal blasts found earlier.
MDF With Aberrant (Malignant) Immunophenotype
Ten patients were classified by MDF as having abnormal blasts cells that did not match the phenotype expected of normal myeloblasts or lymphoblasts. 6, 21 Among these 10 patients, the ANC level the week before MDF was variable: stable in 3 patients, increasing in 4, and decreasing in 3. Eight of 10 patients had cells suggestive of relapse seen in CBC on multiple days. The percentage of blasts in their corresponding CBC ranged from rare to 4%, while the corresponding blasts in their BMA MDF specimens ranged from 0.4% to 35%. The MDF analyses included 9 patients with aberrant myeloblasts and 1 with aberrant lymphoblasts. Seven of 8 evaluable patients with AML in whom relapse occurred retained their pretransplantation immunophenotypic profile.
Nine of 10 patients had cytogenetic and morphologic relapse within 10 days of the flow cytometric assessment. All patients were in apparent remission at the time of the flow cytometric assay. In retrospect, 2 patients, UPNs 9380 and 10827, had preliminary indications of abnormal cytogenetics in process at the time of the flow cytometric analysis. The corresponding specimens analyzed by MDF for these 2 patients were inadequate for evaluation with many damaged or nonviable cells. The final cytogenetic results were not confirmed until after the blasts were defined as aberrant by MDF.
Two patients seemed to have undergone a graft-vsleukemia (GVL) reaction after relapse. 24 Patient 9509
received an allograft to treat refractory secondary AML. Rare cells suggestive of relapse were seen in a day 21 PBS. By MDF analysis, the morphologically normal day 27 BMA revealed 3% myeloblasts with the same aberrant immunophenotype seen pretransplantation. The abnormal pretransplantation cytogenetic markers were absent, but the VNTR showed 20% host cells (elevated). Shortly thereafter, acute graft-v.s-host disease (GVHD) developed. No antileukemic treatment was given, but immunosuppression with cyclosporine was reduced, and eventually, chronic GVHD developed, as did remission, an apparent GVL. The day 93 BMA revealed normal morphologic, MDF, and VNTR studies. The day 303 marrow indicated relapse. A later BMA (day 531) demonstrated the same aberrant immunophenotypic abnormalities as seen in the pretransplantation and day 27 BMAs.
For the second patient with GVL (UPN 10532) with Philadelphia chromosome-positive refractory ALL, flow cytometry, morphologic examination, and cytogenetics on day 16 revealed relapse IFigure 31. After discontinuation of cyclosporine, severe GVHD developed. Multiple MDF and cytogenetic examinations demonstrated the eventual disappearance of the abnormal clone by day 65. The patient remained in remission but died of transplant-related causes on day 172.
Statistical Analyses
The time after transplantation when cells suggestive of relapse were observed in peripheral blood was similar for the The blast cells were characterized as low for CD45 (A and D, red) with high expression of CD10 without CD20 (B and E) and coexpression of CD34 and CD22 (C and F). After the detection of residual tumor cells on day 16, cyclosporine was discontinued, resulting in severe multisystem graft-vs-host disease. The peripheral blast counts detected morphologically declined dramatically from 10% on day 21 until they disappeared from the blood on day 38. Flow cytometry identified 15% aberrant blasts on day 16, 10% on day 21, and only 0.8% in the marrow on day 35. Subsequent weekly analyses between days 65 and 90 showed only normal phenotype cells by multidimensional flow cytometry. On day 136, the blood contained morphologically atypical cells, while flow cytometric analysis showed 2% phenotypically normal myeloblasts and no lymphoblasts. The patient remained in remission with mild liver graft-vs-host disease until he died on day 172 of progressive interstitial pneumonia. PerCP = peridinin-chlorophyll a; Lymph = lymphoblasts; Mono = monocytes; FITC = fluorescein isothiocyanate.
2 MDF groups (median, 65 days for those characterized as normal and 64.5 days for those characterized as abnormal or malignant). The odds of morphologic relapse within 42 days of the MDF test result was 90 times higher among patients whose MDF test result was malignant compared with those for whom the test result was benign ITable 31.
A comparison with other hematologic characteristics for predicting relapse was made. The odds of relapse were higher in patients with a decreasing ANC and a stable ANC compared with patients with an increasing ANC, although the differences were not statistically significant. Similarly, the odds of relapse were higher among patients with blasts observed on multiple days compared with those with a single occurrence of blasts, although the difference was not statistically significant. The odds of relapse were 8.3 times higher among patients transplanted in relapse compared with those transplanted in remission (P = .044).
• Although the associations between 2 of these alternate variables and the probability of relapse were statistically insignificant, the relatively small number of relapses and small number of patients may limit the power to detect differences. Moreover, the apparent strong association seen between MDF status and the probability of relapse might be partially accounted for by 1 or more of these alternate variables. For this reason, a multivariable logistic regression model containing only the alternate explanatory variables was compared with the model containing the alternate variables in addition to the variable indicating MDF status. By using exact methods, the conditional scores test yielded a P value of .007 to reject the null hypothesis that MDF shows no association with subsequent relapse. Therefore, we conclude that the association seen between MDF and the probability of morphologic relapse within 42 days of MDF test is not explained by accounting for other potentially confounding variables.
Discussion
Before the present study, assessing the biologic significance of low numbers of immature cells or cells suggestive of relapse in blood smears often was resolved by watchful waiting. The present study demonstrated that earlier detection of relapse in the HCT setting can be achieved by using a low-cost screening technique, morphologic evaluation of PBS, to trigger a more sensitive and specific test, flow cytometric analysis. The use of MDF demonstrated that benign myeloblasts could be found in the blood on multiple days, may occur after 100 days posttransplantation, and occur in the absence of hematopoietic growth factors. This distinction of benign lymphohematologic precursors or NK cells from leukemic cells was made when the cells in question were present in small numbers (<0.5%). The rapid turnaround time (often within hours of receipt of the specimen), no requirements for the development of specific probes, and detection of aberrant lymphoid and myeloid blasts permits the use of MDF in a routine HCT environment.
In the present study, there was a high correlation between detection of aberrant blasts by flow cytometry and rapid relapse. The odds ratio of relapse among patients with an aberrant MDF phenotype was significantly higher than among patients with benign MDF tests. The odds ratio remained elevated even after adjusting for the other potential variables, ie, decreasing ANC, the frequency of abnormal cells in the CBC count, and relapse or remission status before transplantation. In contrast with the strong predictive value of MDF findings, the value of a decreasing ANC count or the presence of blast cells observed on multiple days was not statistically significant for predicting relapse. In related studies, we found MDF to be a powerful tool for detecting occult AML, 20 ALL, 6 and hairy cell leukemia 25 in BMA and for predicting leukemic relapse in patients who have no overt signs of leukemia in peripheral blood specimens or BMAs.
The aberrant MDF findings often hastened the confirmation of relapse by morphologic examination, cytogenetics or other methods; in 5 of 10 patients whose MDF was interpreted as relapse, the prediction was based on finding only 0.4% to 3% leukemic cells, well below the level of morphologic recognition. The presence of phenotypically aberrant tumor cells after HCT means that the patient is in clinical relapse since these cells will expand to be detectable by morphologic examination or cytogenetics. Our experience suggests an interval of 10 to 14 days from when small numbers of abnormal cells are detected sporadically in blood smears until overt marrow relapse. In an earlier study of MDF, we found that all 12 post-HCT patients with leukemic Shulman e t al / PERIPHERAL BLASTS AFTER HEMATOPOIETIC CELL TRANSPLANTATION lymphoblasts detected by MDF, including 3 without morphologic or cytogenetic identification, experienced relapse within 42 days of the positive MDF analysis. 6 Yet there are no data that demonstrate that a lower tumor burden resulting from an earlier diagnosis of post-HCT relapse translates into a better response to subsequent antileukemic treatments. The specificity of MDF depends on the degree of aberrancy from normal maturational patterns, usually sufficiently high to allow discrimination of benign from leukemic phenotypes, even without a previous pretransplantation phenotypic evaluation. Difficult and possibly false-positive or falsenegative interpretations may occur with low blast counts or in leukemias with little maturational aberration. Sorting the population of interest and performing FISH or VNTR clearly demonstrates whether the cells of interest are of host or donor origin. 2, 3 Like other tests, MDF is subject to technical problems or conditions that hinder interpretation or lead to false-negative results. Improperly obtained aspirates with damaged or nonviable cells resulted in cytogenetically positive but falsely negative MDF results for 2 patients.
This analysis may not accurately represent the proportion of the posttransplant CBC smears with blastic cells that are benign or malignant cells. This small cohort was subject to the selection bias that not all patients with cells suggestive of relapse confirmed in their PBS underwent MDF examination. Therefore, finding 37% of the cases to have malignant cells may be different if a larger nonselected cohort is studied. This hierarchic order of testing using blood smears that were confirmed morphologically as suggestive of relapse to trigger MDF should be studied prospectively in all post-HCT leukemic patients whose CBC contain undefined "suspicious" cells. This would better define the most costeffective situations in which detection of early relapse by MDF is more likely. Our most prudent recommendation based on the results of the present study is that patients who undergo transplantation during first remission and have an increasing ANC and the single appearance of infrequent cells suggestive of relapse in their CBCs might be observed. All other patients, transplanted in relapse, later stages, or the second chronic phase of CML, and refractory anemia with an excess of blasts or the later stages of MDS, should be studied by MDF. 
